Emergency Alert From ANR News Reporter Wayne Crouch
PLEASE look up vaccinia this time I want you to click the links and see for yourself on the government’s own sites it’s in the monkey pox jab and the next few pics are of people who were just touched by someone vaxed and the pics etc are on CDC website and FDA, as is all the info they will scrub it away this will look like a pox outbreak people will be terrified and race to it the jab is more infectious than golden staff.
Vaccine Adverse Reaction Images
The images below show examples of autoinoculation sites and adverse reactions to the smallpox vaccine. Find images of normal reactions on the “major takes” page.
Pictures labeled by CDC are in the public domain. All other pictures are posted with the permission of the copyright holders and may be downloaded for personal use but may not be reproduced without the express permission of the copyright holder.
ACAM2000 (Smallpox Vaccine) Questions and Answers
FDA licensed Smallpox (Vaccinia) Vaccine, Live, with the proprietary name ACAM2000, for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection. The vaccine is manufactured by Sanofi Pastuer Biologics Co. The approval and availability of this second-generation smallpox vaccine in the Strategic National Stockpile (SNS) enhances the emergency preparedness of the United States against the use of smallpox as a dangerous biological weapon.
Questions about Smallpox and ACAM2000
How does ACAM2000 work?
The vaccine is made from a virus called vaccinia, which is a “pox”-type virus related to smallpox but causes milder disease. ACAM2000 cannot cause smallpox; it does not contain the smallpox virus, but rather the “live” vaccinia virus - not dead virus like many other vaccines. For this reason, attentively caring for the vaccination site is important to prevent the virus from spreading from the vaccination site to other parts of the body, or to other people.
ACAM2000 is administered differently than the typical “shot” associated with most vaccinations. A two-pronged stainless steel (or bifurcated) needle is dipped into the vaccine solution and the skin is pricked several times in the upper arm with a droplet of the vaccine. The virus begins growing at the injection site causing a localized infection or “pock” to form. A red, itchy sore spot at the site of the vaccination within 3-4 days is an indicator that the vaccination was successful; that is, there is “a take.” A blister develops at the vaccination site and then dries up forming a scab that falls off in the third week, leaving a small scar. The vaccine stimulates a person’s immune system to develop antibodies and cells in the blood and elsewhere that can then help the body fight off a real smallpox infection if exposure to smallpox ever occurs.
What is smallpox disease?
Smallpox is a serious, highly contagious and often fatal infectious disease caused by the variola virus that emerged in human populations thousands of years ago. A person infected with smallpox develops a rash characterized as raised pocks on the face and body. A person with smallpox has infectious saliva and close contact can spread the virus. The virus could also be spread through other body fluids and contaminated clothing or bed linen.
Hasn’t smallpox been eradicated?
Following a global eradication campaign, which included vaccination, the World Health Organization certified the eradication of naturally occurring smallpox disease in 1980. Until ACAM2000 was licensed, Dryvax, manufactured by Wyeth Laboratories, Inc., was the only vaccine licensed by FDA. Routine vaccination of the American public was stopped in 1972 after the disease was eradicated from the United States. However, smallpox has the potential to be deliberately used as a weapon by terrorists. A large proportion of the population has no immunity and fatality rates could be higher than 25% if smallpox were to be released as a bioterrorist weapon.
Is ACAM2000 different than Dryvax, a vaccine used in the global eradication of smallpox?
Both vaccines are derived from the New York City Board of Health strain of vaccinia, but Dryvax was grown on the skin of calves and then essentially freeze-dried for storage. It was licensed by FDA in 1931 but is no longer manufactured. ACAM2000, a “second generation” smallpox vaccine, is derived from a clone of Dryvax, purified, and produced using modern cell culture technology.
How effective is ACAM2000?
A clinical study to demonstrate ACAM2000 is non-inferior to Dryvax was conducted in each of two populations: those who had never been vaccinated for smallpox (naive) and those who had previous vaccination. For the naive population, the percentage of scar formation at the vaccination skin site or “take rates” were similar to Dryvax vaccinees. For those previously vaccinated, the immune response generated was acceptable for ACAM2000.
Specifically, the clinical study was a multi-center, randomized, controlled study, comparing ACAM2000 to Dryvax. To compare the efficacy in persons who had never been previously vaccinated against smallpox (naive), 780 subjects received ACAM2000 and 257 subjects received Dryvax. The recipients included males and females between the ages of 18 and 30 years. In a study of people previously vaccinated against smallpox, 1,242 subjects received ACAM2000 and 405 subjects, including males and females from 31-84 years old, received Dryvax. The percentage of unvaccinated persons who developed a successful immunization reaction was similar to that of Dryvax. ACAM2000 also was found to be acceptable as a booster in those previously vaccinated for smallpox.
Questions about Adverse Side Effects and Who Should Not be Immunized
Are there any possible side effects associated with the use of ACAM2000?
Yes, health complications can occur after receiving the vaccine, and the risk of experiencing serious side effects must be weighed against the risk of experiencing a potentially fatal smallpox infection.
The vaccine may cause myocarditis and pericarditis, which are inflammation and swelling of the heart and surrounding tissues and can be very serious. Based on clinical studies, myocarditis and/or pericarditis occur in 1 in 175 adults who get the vaccine for the first time.
In the ACAM2000 clinical trial experience, seven individuals of the 2,983 ACAM2000 first-time recipients and three individuals of the 868 Dryvax first-time recipients were suspected to have myocarditis/pericarditis. There were no cases in those subjects who had been vaccinated previously.
Serious health problems, including those that are life-threatening, can also occur in unvaccinated people who are accidentally infected by someone who has recently received the vaccine. In particular, unvaccinated people who are pregnant, or have problems with their heart or immune system, or have skin problems like eczema, dermatitis, psoriasis, and have close contact with a vaccine recipient are at an increased risk for serious problems if they become infected with the vaccine virus, either by being vaccinated, or by being in close contact with a person who was vaccinated. It is very important for the ACAM2000 recipient to properly care for the vaccination site to prevent the virus in the vaccine from spreading and infecting another part of the body and other people.
These types of serious adverse events are similar to those that occurred in the past with other smallpox vaccines.
More commonly observed side effects include: itching, sore arm, fever, headache, body ache, mild rash and fatigue.
Who should not be immunized with ACAM2000?
A healthcare provider may decide not to give ACAM2000 if a person has a weakened immune system (e.g., leukemia, HIV, AIDS, transplant recipients, people with cancer that has spread, and those undergoing treatment with medicines that suppress the immune system such as steroids, prednisone, and cancer drugs). In addition, healthcare providers may decide not to vaccinate individuals with skin conditions such as eczema, dermatitis or psoriasis who are at increased risk of complications.
How will ACAM2000 recipients be informed of its potential risks?
Every person who receives the vaccine is required to receive a Medication Guide approved by FDA (21 CFR Part 208). Medication Guides are printed handouts that are specific to particular medical products, and contain FDA-approved information that can help patients avoid serious adverse events. FDA requires that Medication Guides be issued when the Agency determines that:
- certain information is necessary to prevent serious adverse events
- patient decision-making should be informed by information about a known serious side effect with a product, or
- patient adherence to directions for the use of a product are essential to its effectiveness.
ACAM2000 is the first vaccine licensed with a Medication Guide. FDA has determined that a Medication Guide is necessary for safe and effective use of the product because it could help prevent serious adverse events and inform the recipient of serious risks relative to benefit that could affect their decisions to be vaccinated.
Will ACAM2000 be available to anyone who wants it?
No, the manufacturer has stated that the vaccine won’t be available to the public commercially, meaning it can’t be obtained from a doctor’s office. It has been purchased by the federal government for inclusion within the country’s Strategic National Stockpile, for distribution by the Department of Health and Human Services, in case it is ever needed.
Currently, designated U.S. military personnel receive the vaccine. In addition, laboratory researchers working on certain pox viruses are also be eligible to receive the vaccine.
The vaccine is not recommended for use by the general population, as there is no smallpox disease in the world.
Monkeypox vaccine: what’s available in Australia, and who should get it?
The WHO has declared the virus a global health emergency, while in Australia, monkeypox is now a ‘communicable disease incident of national significance’. Here’s what we know about vaccination
On 28 July Australia’s chief medical officer Paul Kelly declared monkeypox a “communicable disease incident of national significance”. This means disease spread is serious enough that national policy, interventions and public messaging is needed to combat it, along with more resources.
It follows the World Health Organization declaring the spread of monkeypox a global health emergency earlier in July.
The US Centers for Disease Control and Prevention said there have been 20,311 monkeypox cases in 71 countries, including Australia, that have not seen monkeypox spread before. Here’s what we know about the vaccines and who should get vaccinated in Australia.
What vaccines are available for monkeypox?
On 4 August, the Australian government announced it had bought 450,000 doses of the third-generation Bavarian-Nordic vaccine, the first 22,000 of which were due to arrive within two weeks. That vaccine would be prioritised for at-risk groups including men who have sex with men – especially those travelling to countries with a significant outbreak – sex workers, and immunisation providers who are administering the ACAM2000 smallpox vaccine.
The ACAM2000 smallpox vaccine is also registered for use in Australiaand protects against monkeypox, but as it uses a weakened live pox virus it is not suitable for immunocompromised people. Supply of this vaccine is available to states and territories through the national medical stockpile. It hasn’t been widely used, since smallpox has been eradicated.
With more than 70 countries now affected by monkeypox outbreaks, this newer vaccine is in short supply globally.
How do the vaccines work?
The older ACAM2000 vaccine is made from a virus called vaccinia, which is a type of pox virus related to smallpox and monkeypox, but which does not cause either disease, and which is also much milder than both viruses.
Administering the vaccine requires special training.
The skin is repeatedly scratched with a needle dipped into the vaccine. The virus begins to grow at the injection site, causing a red, itchy sore spot, or a “pock” in the days afterwards. It then eventually blisters and scabs over, and may leave a small scar.
The vaccine stimulates the immune system to develop antibodies that can then help the body recognise and then fight an infection if exposure to monkeypox occurs.
There is a risk that the vaccinia virus can be transmitted from the wound site to their close contacts. Those who are severely immunocompromised, who are pregnant, or who have eczema are most at risk, and can suffer serious adverse events either from being vaccinated or exposed to someone who has been. The risk of transmission from a vaccinated person to other people can be reduced by covering the injection site and good hygiene. The site is only infectious until scabbed over.
The newer vaccine, known as Jynneos in Australia, does not carry the same risk and can be used in immunocompromised people and is also safe for pregnant women, children, and those with skin conditions. It is administered more easily, given in two doses four weeks apart, though people already vaccinated against smallpox in the past may only need one dose. It has fewer side effects than ACAM2000, and doesn’t require the same aftercare precautions.
On 28 July Kelly announced the Australian Technical Advisory Group on Immunisation (Atagi) had made recommendations around how this newer vaccine should be used so that health workers are ready to administer it once supply is available in Australia. Kelly did not say when he expects the vaccine to be widely available, and Atagi advice states only that “limited supplies … have been secured by the Commonwealth and some states and territories,” though it is unclear if it has arrived in Australia yet.
Not everyone needs vaccination
Most healthy people recover from monkeypox within a few weeks, experiencing symptoms such as fever, headache, muscle aches, backache, swollen lymph nodes, chills and exhaustion. In some cases, monkeypox may begin with a rash or sores in the mouth and on the face, which may then spread to other parts of the body.
Severe illness and death is a risk in rare cases, particularly in immunocompromised people.
ACAM2000 does protect against monkeypox. But according to Atagi, Jynneos is the preferred vaccine for these vulnerable groups, and it is also the preferred vaccine for use in people exposed to the virus and at risk of developing disease. Vaccination after exposure can prevent disease developing, known as post-exposure prophylaxis.
Atagi advice states that “For healthy non-pregnant adults, where Jynneos is not suitable or not available, ACAM2000 has an established profile and may be considered” for those exposed to the virus or at high risk of exposure.
The good news is monkeypox does not spread easily between people. You need close contact with the lesions, body fluids, or respiratory droplets through extended face-to-face contact with an infected person to be at risk.
With a low number of cases in Australia, contact tracing is straightforward and infection risk is lower, but high-risk communities especially are on alert. Until at least the end of November, monkeypox is a notifiable disease in Australia, which means health authorities must be told of every case.
Who should get the vaccine?
In Atagi advice updated late July, the key risk groups recommended for vaccination include anyone who is a high risk monkeypox close contact within the past 14 days. High risk groups include gay, bisexual and other men who have sex with men who have a high number of sexual contacts are at the highest risk of monkeypox infection.
Those living with HIV, a recent history of multiple sexual partners, participating in group sex, or attending sex on premises venues may also be considered for vaccination, the advice states. Those taking HIV prevention medication due to having a number of sexual partners may also be recommended for vaccination.
Atagi states that sex workers, particularly those whose clients are in high-risk categories, and anyone in risk category planning travel to a country experiencing a significant outbreak, should also have vaccination recommended to them between four-to-six weeks prior to departure.
Healthcare workers who will be administering ACAM200 can be offered either vaccine if they have not previously received a smallpox vaccine. Healthcare workers who will only be administering the Jynneos vaccine and otherwise have no anticipated occupational exposure to monkeypox are not routinely recommended for smallpox vaccination.
For those health workers who have already received a smallpox vaccine in the past, a booster dose is recommended if the previous dose of a smallpox vaccine was given more than ten years prior.
Vaccination is also being offered on a case-by-case basis to high-risk close contacts of monkeypox cases, such as household contacts and health workers.
“Vaccination within four days of first exposure to an infectious case will provide the highest likelihood of prevention of disease,” Atagi says.
I received a smallpox vaccination as a child. Am I still protected against monkeypox?
A systematic review published in 2019 suggests that protection offered against smallpox virus may last more than 20 years after vaccination. A separate small study found protection may last 35 years or longer. It is hoped protection against monkeypox would last similarly.
According to Atagi: “Childhood smallpox vaccination may confer a longer lasting immune response than vaccination during adulthood, however this is uncertain. Those who have previously received a smallpox vaccine are likely to have some residual protection.”